Bio-Plex Multiplex Assays

In December 2022, a groundbreaking law was passed granting the U.S. FDA the authority to consider data from new alternative methods in the preclinical testing phase for new drug development. Among the new methods are 3D cell cultures that mimic human tissues and organs, known as microphysiological systems (MPS). The new law aims to improve clinical outcomes while decreasing reliance on animal testing. In this article, we discuss MPS and review data showing how they can synergize with Bio-Plex Assays.

In this webinar, see how a Bio-Plex Pro Assay could provide a high-throughput culture-free NT50 determination method for current and future SARS-CoV-2 variants.

Current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have reduced the severity of the coronavirus disease 2019 (COVID-19). However, the drastic and quick evolution of the virus poses challenges to the development of durable and efficacious therapeutics for vaccine and antibody developers alike. See how the Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Custom Assay Developer Kit speeds up the qualitative measurement of neutralizing antibodies (NAbs) against new SARS-CoV-2 variants, removing a roadblock in COVID-19 therapeutic development.

Circulation of SARS-CoV-2 in the global population led to the emergence of new variants threatening to undermine vaccine effectiveness. Understanding the immune response and its neutralizing abilities at both the patient level and globally could not only help prevent outbreaks but also mitigate the outcome for future pandemics.

With COVID-19 vaccines now widely available, case numbers in many areas are falling. But the question remains: How long does vaccine-induced immunity last? Measuring isotype-specific antibodies against SARS-CoV-2 and the effectiveness of neutralizing antibodies against variants can help us better understand the duration and breadth of the humoral response. These data are critical to aid public health researchers and inform development decisions for vaccines and therapeutics. Read about the new Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody 11-Plex Panel.

Meet our newest product supporting the fight against SARS-CoV-2: the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel. This qualitative multiplex immunoassay kit quickly and efficiently detects IgG antibodies against four SARS-CoV-2 antigens (nucleocapsid, receptor binding domain, spike 1, and spike 2).

Mice are critical model organisms for the study of neuroinflammation. But tissue quantity is often a limiting factor. In a recent paper, researchers describe a protocol for analysis of 33 cytokines and chemokines using only 50 μl of tissue homogenate. The remaining homogenate can be used for RNA extraction or other analysis.

In vaccine development, safety and efficacy are critical. Recent studies have shown that multiplex immunoassays offer a flexible way to monitor immune responses. With the ever-increasing pressure on scientists to develop a practical COVID-19 vaccine, multiplex immunoassays stand out as a proven tool.

Presented by: Daniel Braunschweig, PhD, Proteomics Field Application Scientist Leader

View on demand

This webinar provides an overview of multiplexing technology for research use with mouse samples and highlights the associated benefits to your drug discovery workflow. Specific topics include:

Presented by: Brett Houser, Bio-Plex Multiplex Immunoassay Product Manager, Protein Quantitation Group

View on demand

Bio-Plex Manager Software is a powerful, intuitive tool used to generate and analyze xMap data. In this webinar you will:

• Learn how to create an assay protocol
• Learn how to acquire data
• Understand basic software parameters
• Learn about general functionality and navigation
• Master optimization of standard curves and export data for further analysis